61090-37-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2,3-Dihydro-4-benzofuranamine is used as a key intermediate in the synthesis of various pharmaceutical compounds for its unique chemical structure and reactivity.
Used in Medicinal Research:
In the field of medicinal research, 2,3-Dihydro-4-benzofuranamine is used as a potential treatment for Parkinson's Disease, leveraging its neuroprotective properties to aid in the management and treatment of this neurological condition.
Used in Organic Chemistry:
2,3-Dihydro-4-benzofuranamine is utilized as a precursor in the synthesis of other important organic compounds, contributing to the development of new chemical entities and materials in organic chemistry.
Used in Neuroprotective Agents Development:
In the development of neuroprotective agents, 2,3-Dihydro-4-benzofuranamine is used for its potential to protect neurons from damage or degeneration, which is crucial in the study and treatment of neurodegenerative diseases.
The applications of 2,3-Dihydro-4-benzofuranamine are diverse, reflecting its importance in both the synthesis of pharmaceuticals and as a subject of research for potential therapeutic uses. Its versatility in chemical reactions and biological activities positions it as a valuable compound in scientific and medical fields.

InChI:InChI=1/C8H9NO/c9-7-2-1-3-8-6(7)4-5-10-8/h1-3H,4-5,9H2

Upstream product

• 76093-72-6 N-[2-(2-hydroxyethyl)-3-methoxyphenyl]pivalamide 
• 536-90-3 m-Anisidine 
• 56619-93-3 N-(3-methoxyphenyl)pivalamide 
• 69227-65-2 4-nitro-benzofuran 
• 801282-09-7 C₁₃H₁₇NO₂ 
• 327183-29-9 tert-butyl 2-(2-hydroxyethyl)-3-methoxyphenylcarbamate 

Downstream Products

• 196597-27-0 N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide 
• 170728-95-7 7,8-dihydro-1H-furo[2,3-g]indole 

Relevant academic research and scientific papers

COMPOUND PERTAINING TO NEUROPOIESIS AND DRUG COMPOSITION

A composition for activating neurogenesis or the growth of neurons is provided. In one or more embodiments, a composition contains as an active ingredient a compound with a DYRK inhibitory capacity or a prodrug thereof or a pharmaceutically acceptable sal

COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR

The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development

2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, Ar, m and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, Q, G, Ar, m, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, A, B, D, E, G, Ar, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, R6, B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.